PSA Velocity and Doubling Time — Why a Single Number Tells You Nothing
Anyone over 50 doing routine PSA testing has had this experience: the result comes back, the absolute number looks vaguely concerning or vaguely fine, and there's no obvious way to know what it means. A PSA of 2.4 is fine for some people and rising for others. A PSA of 4.5 is below the historical screening cutoff but might still warrant attention. The single number rarely tells you anything actionable — the trend is what urologists actually use.
Why a single PSA value is rarely actionable
PSA — prostate-specific antigen — is a protein made by prostate tissue. Both healthy and cancerous prostate cells produce it. Levels vary day to day for many reasons:
- Recent ejaculation elevates it (within 48 hours)
- Vigorous exercise elevates it (especially cycling)
- Prostatitis (infection or inflammation) can elevate it dramatically
- Recent prostate procedures (DRE, biopsy, catheter) elevate it
- BPH (benign prostatic hyperplasia) elevates it gradually as the prostate grows
- Prostate cancer can elevate it — but slowly, and not always
Random biological variation alone can swing measurements by 15–20%. So a PSA that jumps from 2.5 to 3.0 between two annual draws doesn't mean much. A PSA that climbs from 2.5 to 4.2 to 6.1 across three years means more.
PSA velocity
PSA velocity is the rate of change — ng/mL per year. It's typically computed as the slope across multiple readings. Common (not absolute) thresholds for "warrants further attention":
- >0.75 ng/mL per year on a baseline elevated value (PSA >4)
- >0.35 ng/mL per year at lower baselines, especially with younger age
A consistently rising PSA — even within the "normal" range — is more concerning than a stable elevated PSA, all else equal. Cancer rises, BPH rises slowly, infection spikes and falls.
PSA doubling time
Doubling time asks the same question differently: at the current rate of rise, how many months until your PSA doubles?
It's calculated by fitting an exponential curve to your readings — specifically by linear regression on ln(PSA) against time. The slope of that fit gives you the doubling rate.
Why log-linear? Because cancer growth is generally exponential rather than linear. If a tumor is doubling at a constant rate, the PSA produced should also double at a constant rate. So the doubling time is a more biologically meaningful metric than absolute change.
Common thresholds:
- Doubling time <12 months: typically warrants oncology evaluation
- Doubling time 12–24 months: closer follow-up, possible imaging
- Doubling time >24 months: continued monitoring, lower urgency
- No rise (or falling): reassuring; continue routine screening interval
These are guidelines, not absolutes. A doubling time of 8 months in someone with a stable BPH history and no other concerning findings is different from the same doubling time in someone with a rising trajectory and a positive family history.
Why both metrics matter
Velocity and doubling time describe the same underlying trend in different ways, and one or the other will resonate with different clinicians. PSA velocity is the older metric and is widely understood. Doubling time is more biologically grounded and is what oncologists tend to use, especially after a known cancer diagnosis to decide whether and how to treat.
A trend tracker that surfaces both lets you see your data the way your urologist will frame it.
What "discuss with urology" means in practice
A rising PSA trend that crosses thresholds doesn't mean you have prostate cancer. It means the next step is more information. That typically includes:
- Free PSA ratio — what percentage of your total PSA is "free" (not protein-bound). Higher free fraction is associated with BPH; lower with cancer.
- PSA density — total PSA divided by prostate volume on ultrasound. Adjusts for the fact that bigger prostates make more PSA.
- MRI of the prostate — multiparametric MRI has gotten dramatically better and is increasingly the next step before biopsy. Identifies suspicious lesions and can spare unnecessary biopsies.
- Biopsy — historically transrectal ultrasound-guided, increasingly transperineal MRI-targeted. Only done when MRI or other findings warrant.
The trend toward MRI-first is one of the most important shifts in prostate cancer screening in the last decade. It substantially reduces overdiagnosis (catching cancers that would never have caused harm) while improving detection of clinically significant cancers.
The screening debate, briefly
The USPSTF gives PSA screening a "C" recommendation (individual decision-making) for men 55–69, and recommends against routine screening for men 70+. The thinking is that population-level screening catches a lot of indolent cancers that wouldn't have caused harm, leading to overtreatment and side effects (incontinence, erectile dysfunction) that can be worse than the disease.
For men with a family history of prostate cancer, African ancestry, or other elevated risk, the calculus shifts toward more screening. For men in the average-risk middle ground, it's a discussion to have with a primary care provider rather than a default recommendation.
If you ARE doing routine PSA screening, tracking the trend matters more than tracking absolute numbers. Which is what this tool does.
Skip the spreadsheet
The PSA Tracker tool plots your readings on an SVG line chart with a 4.0 ng/mL reference line, surfaces both PSA velocity and doubling time computed from the actual fits (linear for velocity, exponential for doubling), and color-codes the trend metrics so you can see at a glance whether the trajectory is concerning. Per-row "vs previous" delta in the history list. Same on-device privacy as the rest of /health.
The short version
A single PSA tells you very little. The trend across multiple readings tells you most of what matters. Velocity in ng/mL per year and doubling time in months are the two metrics urologists use — both worth tracking, both computed automatically from a series of values. A rising trend warrants conversation, not panic; modern workup leans on MRI before biopsy, which has substantially improved the screen-don't-overtreat balance.